The Impact of ICH E6(R3) on Biospecimen Management

The transition from ICH E6(R2) to ICH E6(R3) marks a pivotal shift in regulatory expectations for biospecimen management in clinical research. With an expanded emphasis on risk-based quality management, enhanced data governance requirements, and increased sponsor oversight responsibilities, organizations must evolve their internal processes to maintain compliance.

This insightful on-demand webinar — featuring regulatory experts Edye Edens and Aman Khera, alongside Slope CEO and Co-founder Rust Felix — explores how ICH E6(R3) will redefine biospecimen management practices. Don't miss this opportunity to prepare for the future of clinical research.

Viewers will:

• Gain a clear understanding of the ICH E6(R3) language that directly impacts biospecimen operations.
• Learn how to proactively align biospecimen management practices with the new regulatory framework.
• Discover how to assess compliance ahead of the EMA's July implementation deadline.